ACTHAR
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
ACTHAR by Sanofi is unknown. Approved for exacerbations of multiple sclerosis in adults, acute exacerbations of multiple sclerosis in adults. First approved in 1950.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTHAR is a repository corticotropin injection approved in 1950 for acute exacerbations of multiple sclerosis in adults. The drug stimulates the adrenal cortex to release cortisol, corticosterone, aldosterone, and weakly androgenic substances. ACTHAR also binds to melanocortin receptors through mechanisms not fully understood but involving cyclic AMP signaling. It represents an older immunomodulatory approach to MS management in a treatment landscape now dominated by disease-modifying therapies.
$0.4BPart D
Mechanism of Action
unknown. Acthar Gel and endogenous ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Prolonged administration of large doses of Acthar Gel induces hyperplasia and hypertrophy of the adrenal cortex and continuous high…
Indications (2)
Worked on ACTHAR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.